Amicus Therapeutics (FOLD) Shares are Down -0.99%

Amicus Therapeutics (FOLD) has risen sharply, recording gains of 10.09% in the past 4 weeks. However, the stock has corrected -0.99% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 3.13% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

Amicus Therapeutics (NASDAQ:FOLD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $5.90 and $5.81 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.02. The buying momentum continued till the end and the stock did not give up its gains. It closed at $6.00, notching a gain of 2.21% for the day. The total traded volume was 1,210,942 . The stock had closed at $5.87 on the previous day.


The stock has recorded a 20-day Moving Average of 4.12% and the 50-Day Moving Average is 4.51%. Amicus Therapeutics, Inc. has dropped 25.47% during the last 3-month period . Year-to-Date the stock performance stands at -38.14%.

Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.